Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock

Key Points

• Elanco CFO Robert Vanhimbergen purchased 4,200 shares at an average price of $23.08, investing $96,936 and increasing his holdings by 3.15% to 137,516 shares.
• Elanco’s latest quarterly results exceeded expectations, with EPS of $0.34 versus the $0.27 consensus and revenue of $1.37 billion, up 10.2% year over year. The company issued third-quarter EPS guidance of $0.19–$0.22 and full-year guidance of $1.10–$1.16.
• ELAN shares traded at $22.26, while analysts maintained a broadly positive outlook with a consensus “Moderate Buy” rating and a $29.09 price target; institutional investors own 97.48% of the stock.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) CFO Robert Vanhimbergen acquired 4,200 shares of the company's stock in a transaction on Friday, August 7th. The stock was bought at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the purchase, the chief financial officer owned 137,516 shares in the company, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Elanco Animal Health Stock Up 0.6%

ELAN stock traded up $0.14 during midday trading on Monday, reaching $22.26. The company had a trading volume of 22,469,851 shares, compared to its average volume of 5,703,481. The company has a 50 day moving average of $24.70 and a two-hundred day moving average of $24.08. The company has a market capitalization of $11.12 billion, a P/E ratio of -54.29, a PEG ratio of 1.32 and a beta of 1.67. Elanco Animal Health Incorporated has a 1 year low of $16.89 and a 1 year high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.31 billion. During the same period in the previous year, the company posted $0.26 EPS. Elanco Animal Health's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Trading of Elanco Animal Health

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Elanco Animal Health during the 2nd quarter valued at approximately $1,202,198,000. UBS Group AG increased its position in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company's stock worth $331,669,000 after buying an additional 5,961,457 shares during the period. Sei Investments Co. increased its position in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company's stock worth $135,214,000 after buying an additional 4,975,721 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock worth $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company's stock worth $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on ELAN shares. Wall Street Zen lowered Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. Piper Sandler reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. TD Cowen lifted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, June 18th. UBS Group boosted their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday. Finally, JPMorgan Chase & Co. increased their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source